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Abstract with gonadotrophin releasing hormone
Objective—To study the resumption of (GnRH) agonists with variable potencies and 
puberty and the final height achieved in different routes of administration. GnRH ago- 
children with central precocious puberty nist treatment causes hormonal suppression
and thereby influences secondary sexual char­
acteristics, growth, and bone maturation.' 8 
Some investigators suggest that delaying
(CPP) treated with the GnRH agonist 
triptorelin.
Patients—31 girls and five boys with C PP 
who were treated with triptorelin 3.75 m g puberty does not improve final height progno- 
intramuscularly every four weeks. Girls sis, as the decreased rate of epiphysial matura- 
were treated for a mean (SD) of 3.4 (1.0) tion is offset by a decrease in growth hormone
years and were followed up for 4.0 (1.2) secretion and growth rate. 9
years after the treatment was stopped. Recently, various studies reporting final
Results—The rate of bone maturation height and the reversibility of the gonadal axis
decreased during treatment and the pre- on discontinuation of treatment have been
dieted adult height increased from 158.2 published.10'17 Most of these results are based
(7 .4 ) cm to 163.9 (7.5) cm at the end of upon agonist treatment given by daily subcuta-
treatment (p<0.001). When treatment was neous injections or intranasal application. It
stopped bone maturation accelerated, re- was suggested that auxological improvement
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depends on a continuous and full suppression 
of gonadal steroid production.1” Furthermore, 
improved results have been documented in 
children with young (bone) ages.1,1 
We have shown that treatment of children 
ing final height (r = 0.75, p<0.001). Bone with CPP with the slow release GnRH agonist
triptorelin is effective in continuous suppres­
sion of gonadal activity.7 20 
In this paper we present the data on the
suiting in a final height of 161.6 (7.0) cm, 
which was higher than the predicted adult 
height at the start of treatment (p<0.001). 
Height at the start o f treatment was the 
most important factor positively influenc-
age at cessation of treatment negatively
P aed ia trics , G roningen  influenced final height (r  = -0.52, p
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0.03). A negative correlation between bone
age and height increment after discon- resumption of puberty and the adult height
tinuation of treatment was observed attained in children with CPP who were
(r = -0.85, p = 0.001). Residual growth treated with the slow release GnRH agonist
capacity was optimal when bone age on triptorelin. 
cessation of treatment was 12 to 12.5 
years. Body mass index increased during
treatm ent and remained high on cessa- Methods
tion. At final height, the ratio of sitting p a t ie n t s
P aed ia trics , L im burg  height to subischial leg length was normal. Thirty six patients (31 girls and five boys) with
Menarche occurred at 12.3 (1.1) years, CPP achieved a final height following treat-
and at a median (range) of 1.1 (0.4 to 2.6) ment with triptorelin (D-Trp6~LHRH) at a
years after treatment was stopped. The mean dose of 96 (SD 25) |.ig/kg intramuscu-
ovaries were normal on pelvic ultrasonog- larly repeated every four weeks. The diagnostic
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criteria for CPP have been described in the
Conclusions—Treatment of CPP with past and are summarised as follows: the 
triptorelin increases final height, with appearance of secondary sexual characteristics 
normal body proportions, and seems to before the age of 8 and 9 years in girls and boys
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increase body mass index. The best results respectively, a bone age/height age ratio >
were achieved in girls who were taller at including a pubertal luteinising hormone (LH) 
the start of treatment. Puberty was re- response in a GnRH test.7 Twenty eight 
sumed after treatment, without the occur- patients (25 girls and three boys) received only
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rence of polycystic ovaries.
(Arch Dis Child 1996;75:292-297)
triptorelin, whereas eight patients (six girls and 
two boys) were treated with buserelin subcuta- 
neously (27 -30  months) or cyproterone acetate
Keywords: central precocious puberty, GnRH agonist, orally (6 -40  months) before starting triptore-
linal height.
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lin.
A computerised tomographic (CT) scan or 
central magnetic resonance imaging (MRI) of the 
precocious puberty (CPP) have been treated brain, or both, was performed in all patients: in
more than a decade children with
jp 'in a l height in precocious puberty after treatment zvith GnRH agonist
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24 girls CPP was considered idiopathic, in four 
girls there was infantile encephalopathy, two 
girls had been operated on for an astrocytoma, 
and in one girl a hamartoma was found. In 
none of the girls with organic CPP was growth 
hormone secretion evaluated. Three of the five 
boys were suffering from neurofibromatosis, 
one boy was operated on for an arachnoid cyst, 
and in one boy the CPP was idiopathic. None 
of the boys with neurofibromatosis underwent 
radiotherapy or surgery. Because no growth 
impairment was observed in these three boys, 
growth hormone secretion was not evaluated. 
The boy operated on for an arachnoid cyst was 
evaluated before GnRH agonist treatment was 
started, and a normal growth hormone res­
ponse to arginine stimulation (GH >20 mU/1) 
was shown.
The patients were treated for at least two 
years. After discontinuation of triptorelin they 
were evaluated each subsequent year until the 
final height was achieved. Final height was 
considered to be attained when the bone age 
was 5:15.0 years in girls and ^16.0 years in 
boys or when height velocity was <1.0 cm/year 
for a minimum period of one year, or both. 
Once the final height was attained, pelvic ultra­
sonography was performed using Acuson 
equipment (Mountain View, California, USA) 
with 3.5 or 5 MHZ transducers.
GROWTH EVALUATION
On initiating the study and subsequently every 
three months during the treatment and every 
six to 12 months after the treatment was 
discontinued, the patients underwent a physi­
cal examination including measurement of 
height, sitting height, and weight, and record­
ing of secondary sexual characteristics. Weight 
was expressed as a quotient using the body 
mass index (BMI) (weight/height2) and BMI 
SD score for chronological age (BMI SDSCA) 
and bone age (BMI SDSBA), using French ref­
erence values.21
Height was expressed as SD score for 
chronological age and bone age, using national 
growth references.22 When measured parental 
heights were available, target height was calcu­
lated using the following formula: (sum of the 
height of the parents ± 12) /2 + 3 cm. Target 
height range was defined as target height ± 1 
SD. For adult females 1 SD amounts to 6.2 
cm.22
The ratio of sitting height to subischial leg 
length was expressed as SD score for chrono­
logical age (SH/LL SDSCA) using reference 
values obtained from the Zurich longitudinal
growth study.23
Bone age was determined by one observer
(WO) according to the method of Greulich 
and Pyle, and predicted adult height was deter­
mined using the tables of Bayley and Pin-
neau.24
Strictly speaking, adult height prediction is 
only applicable under physiological circum­
stances, and has an inherent tendency to over­
estimation in CPP. However, changes in pre­
dicted adult height can reasonably be used as a 
measure of efficacy using treatment such as a
GnRH agonist. In this study we have defined
change in predicted adult height as the 
difference between final height and the pre­
dicted adult height at the start of treatment.
STATISTICAL ANALYSES
All results are expressed as mean (SD), unless 
indicated otherwise. In the auxological evalua­
tion the Wilcoxon signed rank test was used to 
determine differences within each group and 
the Mann-Whitney U test was used for 
determining differences between groups. Pear­
son correlation analysis was carried out to 
assess linear associations. To determine the 
effects of a number of auxological variables 
upon final height, a stepwise multiple 
regression analysis was performed using final 
height as the dependent variable. The variables 
were chronological age, bone age, height, and 
BMI (all at the start of treatment); bone age at 
the time of discontinuation of treatment; target 
height, duration of treatment, and chronologi­
cal age at attainment of final height.
Written informed parental consent was 
obtained before the start of treatment. The 
study was approved by the ethics committees 
of the participating university hospitals.
Results
During treatment, regression in secondary 
sexual characteristics occurred because prepu­
bertal oestradiol and testosterone levels were 
attained in girls and boys, respectively, as has 
been reported in the past.7 20 No local or 
systemic side effects were observed. One girl 
developed type 1 diabetes mellitus several 
months after discontinuation of triptorelin.
AUXOLOGICAL EVALUATION
No significant differences in chronological age, 
bone age, height, predicted adult height at the 
start of treatment, or in final height and target 
height were found between the group of previ­
ously untreated patients compared to the 
previously treated group (Mann-Whitney U 
test). Therefore, all data were compiled to­
gether.
Baseline data
In girls, chronological age at the start of 
triptorelin treatment was 7.7 (0.8) years (table 
1). The onset of puberty as reported by the 
parents was 6.0 (2.0) years. In boys, chrono­
logical age at the start of treatment was 7.9 
(1.9) years.
The actual height at the start of treatment in 
girls is reported in table 1. It was 140.1 (8.4) 
cm (+2.10 (2.21) SD score) in boys.
Patients were treated for a period of 3.4 (1.1) 
(F) and 4.2 (0.8) (M) years, respectively, and 
were followed up for 4.0 (1.2) (F) and 3.9 (0.9) 
(M) years after the discontinuation of treat­
ment.
Height velocity
Before initiating treatment the height velocity 
was 8.0 (2.3) cm/year in girls and 10.4 (4.8)
cm/year in boys.
In girls, during treatment height velocity
decreased to low values in the last year of treat­
ment (table 2). An increase in height velocity
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Table 1 Effect o f triptorelin treatment in girls on mean 
(range or SD ) chronological age, bone agey actual height, 
predicted adult height, height SD  score for chronological age 
and bone age, sitting height/leg length SD  score for 
chronological age, and body mass index SD  score for 
chronological and bone age, evaluated at the start and at 
the end o f treatment and at fina l height
Table 2 Height velocity and bone maturation (A bom  
age/A chronological age) daring and after discontinuation 
o f triptorelin treatment in girls
Height 
velocity 
No (cm ¡year)
A Bone age IA 
chronological 
No age
No
S ta n  of 
treatment
End of 
treatment Last visit
Chronological 31 7.7 (5.1 to 11,1 (9.4 to 15.1 (12.7
age (years) 9.2) 13.1) to 17.5)
Bone age 31 10.8 (9.4 12.5 (11.5 16.0 (15.0
(G&P) to 12.5) to 13.5) to 17.0)
(years)
Actual height 31 137.3 152.4 161.6
(cm) (117,9 to (140,6 to (146 to ,ft K
152) 161.8) 174.9) ’
Predicted adult 31 158.2 163.9 -----
height (cm) (145,5 to (148.7 to
176) 181.6)”
Height SDSca 31 1.60 0.58 -1.08 , 1' il
(1.21) (1.10)c (1.12)
Height SDSba 31 -1.31 —0.71 -1.08 ,il t
(0.95) (0.98)c (1.12) *
Sitting 15 -0.36 0.06 -0.08
height/leg (1.53) 0 .21) (0.97)
length
SDSca
Body mass
index as:
s d s ca 30 1.70 1.80 (1.41) 1.44 (1.46)
(1.31)
SDSba 30 0.66 1.29 (1.29)c 1.44 (1.45)c
(1.05)
Whole treatment 
period 
Last year of treatment 
1 st year after stopping 
treatment 
2nd year after stopping 
treatment
31 4.5 (0.9)
25
25
3.7 (1.0)
4.8 (1.8)*
31 0 .52 (0 .21 )
19 0.47 (0.34) 
19 0.81 (0.36)*
25 2 .9 (1 .5 )tt 19 1.34
(0.36)+i
G&P = Greulich and Pyle.
a = p < 0.001 compared with predicted adult height at the start 
of treatment; b = p < 0.001 compared with predicted adult 
height at the end of treatment; c = p < 0.001 compared with 
start of treatment; d = p < 0.001 compared with the end of 
treatment; e = p < 0.05 compared with the start of treatment.
was only observed in the first year after discon­
tinuation of treatment. In boys the same 
pattern was observed (data not shown).
* p < 0.001 compared with die last year of treatment; f  P < 0.01 
compared with the 1st year after stopping treatment; $ P < 0.01 
compared with the last year of treatment.
resulting in an improvement of predicted adult 
height at the start of treatment compared to 
predicted adult height at the point of discon­
tinuation of treatment (table 1 ) (fig 1 ).
After discontinuation of treatment bone 
maturation accelerated immediately in the first 
year, with higher A bone age / À chronological 
age ratios in the second year (table 2).
In boys, the A bone age / A chronological age 
ratio during treatment was 0.56 (0.34), result­
ing in an improvement of predicted adult 
height from 177.4 (12.6) cm at the start of 
treatment to 182.5 (15.7) cm at the point of 
cessation of treatment (fig 1). After discontinu­
ation of treatment the same pattern was 
observed as in girls (data not shown).
Change in bone maturation and predicted adult 
height
Bone age at the start of treatment was 10.8 
(0.7) years in girls (table 1) and 11.0 (2.6)
Final height
In girls, the changes in height velocity and bone 
maturation resulted in a final height of 161.6 
(7.0) cm, which was less than that predicted at 
cessation of treatment [163.9 (7.5)] and less 
than target height [168.7 (6.4) cm] [+0.06
(1.03) SDS] (n=26), but higher than predicted 
adult height at the start of treatment [158.2
(7.4) cm] (fig 1) (table 1). A positive change in
years in boys. In girls, bone maturation, pre icted a ult height of 3.5 (4. ) cm (range
expressed as A bone age / A chronological age V* cm) was achieved.
ratio, decreased during treatment (table 2), n t e five boys, fina ieight was 71.5(8.5)
cm [-1.57 (1.27) SDS] which, similarly, was
less than predicted at cessation of treatment,
but also less than the predicted adult height at
start of treatment.
Predicted height at start of treatment 
Predicted height at end of treatment
...1 Final height
Target height
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Correlation between final height and other 
variables
In girls a positive correlation was shown 
between final height and height at the begin-
ning and at the 
p<0.001, and r
of treatment (r = +0.75, 
+0.84, p<0.001 respec-
tively). A negative correlation was observed 
between final height and bone age at the end of
treatment (r 0.52, p Furthermore
a negative correlation between chronological 
age and bone age at the end of treatment and 
the height increment after treatment was found
(r 0.45, p = 0.005, and r 0.85, p<0.001
(fig 2), respectively). No linear correlation was 
observed between final height and chronologi­
cal age or bone age at start of treatment or the
treatment
Girls 
<n = 26)
Boys 
(n = 5)
demonstrated betw« 
height (r = +0.32, p 0.05).
Figure 1 Predicted, final, and target height in girls ( n -2 6 ) and boys (n -5 )  during and  
after treatment with triptorelin. *p<0.05, fp < 0 .01.
Stepwise multiple regression analysis re- 
aled that final height (y) was influenced most
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start and at the end of buserelin was 0.28
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SDSba at the start of buserelin treatment was 
not significantly different from BMI SDSilA at 
the start of triptorelin. On the other hand BMI 
SDSba at the end of treatment was signifi­
cantly higher in the triptorelin group than in 
the buserelin group (p<0.001). (There was no 
difference in bone age at the start of therapy 
between the two groups.)
Bone age (years) at end of treatment
Figure 2 Final height minus height at the end of 
triptorelin treatment as a function of bone age (years) at 
the end of triptorelin treatment in girls (n —31).
MENSES AND PELVIC ULTRASOUND EVALUATION
Menarche occurred at 1.1 
(range: 0.4 to 2.6 years) after discontinuation 
of treatment and at a chronological age of 12. 3 
significantly by height at the start of treatment (1.1) years. At the final consultation., five of the 
(%j). Other significant factors were the bone 31 girls were using oral contraceptives. The 
age at the point of starting of treatment (x2) menstrual cycles were regular in 26 out of the 
and at discontinuation of treatment (x;) and 31 girls.
the duration of treatment (x4) (y = +0.91 x x } 
— 3.6 x x2 — 5.0 x x -.j + 1.5 x x4 + 132.5; R 
0.89; residual SD = 2.46; p<0.001).
Pelvic ultrasonography was performed in 22 
girls. Four of them were using contraceptives 
and in all four girls normal ovaries were
Twenty four of the 31 girls showed a positive observed. In the remaining 18 girls, the volume 
change in predicted adult height (median 5.2 of the uterus 33.9 (15.6) cm’, which represents 
cm, range 0.5 to 10.5 cm) (group A); however, the upper limit of the normal adult volume.
seven of the 31 girls (group B) reached a final 
height below predicted adult height at start of 
treatment (median -2.9 cm, range —0.9 to 
—4.8 cm). The most important differences
The volumes of the ovaries were within the 
normal range, at 7.9 (3.9) cm1 compared to the 
reference value of 7.4 (4.8) cmV5 
In four girls, one of the ovaries was larger
between these groups were a younger age at than normal. In two of these, 2-3 cysts with a
start of treatment in group A [7.5 (0.8) v 8.4 diameter ^0.6 cm were visualised, coinciding
(0.6) years, p = 0.01], a higher bone age/ with the norm for this stage of puberty.17 In the
chronological age ratio at start of treatment in remaining two girls, 8-10 cysts of ^0.6 cm
group A [1.45 (0.15) v 1.29 (0.08), p = 0.01], diameter were observed. The menstrual cycles
and a longer period of treatment in group A were regular in these four girls. In the ovaries of
[3.7 (1.1) years v 2.5 (0.7) years, p = 0.02]. the remaining 14 girls, a maximum of two to
In 26 girls target height was available, six cysts with a ^ 0 .9  cm were
Sixteen of these girls (62%) final observed. In two of the 14 girls3 were
height within the target height range, whereas documented with a diameter of 2.0 cm. How-
10 did not. ever, this was observed 12 to 14 days after the 
first day of the menstruation, that is, at the 
point of ovulation.Change in body proportions and composition 
The SD score of the ratio of sitting height to
subischial leg length at final height was normal Discussion
in girls, at 0.07 (0.98) (n=26). In 15 girls the This study shows that adult height in girls can
ratio SHLL SDSCA was known during treat- be increased by treatment with the slow release
1). No GnRH agonist triptorelin, although less than
would be expected at the point of discontinua-
ment and at final height 
significant changes were observed.
BMI SDSf ' a in girls at start of treatment was tion of treatment.
higher than the reference population and it did Final height in our girls was 161 (7.0) cm,
not change significantly during and alter treat- greater than the final height of untreated girls
ment (table 1). BMI SDS H A at start of in the studies of T h am d ru p '[151.3 (8.8) cm, 
n = 26], Sigurjonsdottir and Hayles'7 [152.7treatment was normal and increased during 
treatment (table 1). It did not change after dis- (8.0) cm, n = 34], and Paul et a l1,1 [152.7 (8.6), 
continuation of treatment. The same pattern n = 93]. The positive change in predicted adult 
was observed in boys. height of 3.5 cm lies between the values of 2.4 
to 6.2 cm reported in two other studies where 
daily subcutaneous preparations were used."
in
We compared the BMI SD score data of our 
patients with those from a group of 23 girls
treated daily with subcutaneously buserelin, Using triptorelin a
another GnRH agonist, for two years. ’ In this predicted adult height of 6.5 (1.4) cm was
buserelin group [chronological age 6.0 (1.7) reported by Brauner et al3 despite the fact that
years; bone age 9.9(2.2) years at the start of the inclusion criteria used were similar to
treatment] BMI SDSCA and BMI SDSBA were ours. The most remarkable positive change in 
calculated at the start and at the end of buser- predicted adult height— 10 cm—-was
was notelin therapy (BMI at final 
known in this group of girls). BMI SDSCA at
by Paul et al in a group of girls treated before 5 
years of age.'” This tendency for young patients
the start and at the end of the treatment was to obtain a greater positive change in predicted 
1.07 (1.00) and 1.30 (1.05) respectively, not adult height was also observed in our popula- 
significantly different from the equivalent data tion: in the girls who had a positive change in
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predicted adult height of 5.2 cm (range 0.5 to
10.5 cm) (group A), chronological age was sig­
nificantly lower than in those girls who had a 
negative change in predicted adult height. 
Therefore age at the onset of treatment seems 
to play an important role. Only four girls in our 
group were younger than 7 years of age at the 
start of treatment; hence we could not show a 
significant relation between age at start of 
treatment and the final height obtained.
Height at start of treatment proved to be the 
most important positive factor influencing final 
height, as demonstrated by multiple regression 
analysis and by a positive correlation coef­
ficient (r = +0.75), a characteristic that is also 
described in normal puberty.28 Final height 
showed a weak association with target height, 
as also shown by Paul et al.19 Only 62% of the 
girls with a known target height reached a final 
height within the target height range. However, 
this weak association between target height and 
final height is similarly identified in the normal 
population (0.45).29
In contrast to other studies, no improvement 
of adult height was demonstrated in boys.11 19 
The most plausible explanation for this differ­
ence is that three out of the five boys were suf­
fering from neurofibromatosis, a condition 
which itself is associated with growth impair­
ment, and in which the development of 
complications such as optic nerve glioma may 
lead to growth hormone insufficiency. On the 
other hand, in some cases growth impairment 
has been described independently of growth 
hormone levels.30 In our patients growth 
hormone secretion was not evaluated.
The difference in final height as predicted at 
the point of discontinuation of treatment and 
the actual final height attained is caused by a 
moderate growth acceleration after cessation of 
treatment and a definite accelerated bone 
maturation within the same period. The same 
tendency has been described by Oerter et al.12 
As suggested before, the post-therapy level of 
gonadotrophins and sex steroids rises more 
rapidly than in normal puberty, and higher lev­
els are reached in a shorter period of time.20 
This results in a shorter period of growth and 
eventually a final height that is less than the 
predicted adult height at the point of discon­
tinuation of treatment.
In addition to height at start of treatment, 
bone age at the point of discontinuation of 
treatment is another important negative factor 
contributing to final height. As shown in fig 2, 
residual growth capacity is greater before a 
bone age of 12.0 to 12.5 years. For this reason 
discontinuation of GnRH treatment might be 
considered at a bone age of 12 to 12.5 years.
Triptorelin treatment did not influence body 
proportions, as normal ratios of sitting height 
to subischial leg length were observed at the 
point when final height was reached.
In girls, BMI SDSCA was increased at start 
of treatment and did not change during or after 
discontinuation of treatment. On comparison 
of our data with those of Marti-Henneberg, 
who described the normal course of BMI dur­
ing early, normal, and late puberty, the 
increased BMI SDSCA at start of treatment
appears to be a natural event.31 Since children 
with CPP who had been exposed to sex 
steroids underwent a pubertal growth spurt 
and subsequently developed accelerated bone 
age, it would be better to use the index BMI 
SDSba. Using this index, a comparison can be 
made between the girls with CPP and those 
with normal age of onset of puberty at similar 
bone ages. The index was normal at start of 
treatment and increased during treatment, 
suggesting that triptorelin increases BMI, as no 
change in BMI SDSba was observed during 
buserelin treatment.
In our patients a rapid resumption of 
puberty was observed, menarche occurring 1.1 
years (range 0.4 to 2.6 years) after withdrawal 
of treatment, at a mean age of 12.3 (1.1) 
years.20 This is comparable with the results of 
other investigators." 32 Ultrasound evaluation 
showed normal ovaries 4.0 (1.2) years after 
discontinuation of treatment. In contrast to the 
report by Adams et al> no evidence of 
polycystic ovaries was found.17
We conclude, therefore, that treatment with 
the depot GnRH agonist triptorelin increases 
final height in girls without giving rise to 
abnormal body proportions. The best results 
are obtained in girls with a greater height at the 
point of starting treatment. After withdrawal of 
therapy, resumption of puberty occurs rather 
rapidly, without evidence for development of 
polycystic ovaries. Triptorelin seems to in­
crease BMI. From an auxological point of 
view, discontinuation of triptorelin in girls 
might be considered at a bone age of 12.0 to
12.5 years.
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